HK1254200A1 - 氧肟酸三萜系化合物衍生物 - Google Patents

氧肟酸三萜系化合物衍生物 Download PDF

Info

Publication number
HK1254200A1
HK1254200A1 HK18113340.0A HK18113340A HK1254200A1 HK 1254200 A1 HK1254200 A1 HK 1254200A1 HK 18113340 A HK18113340 A HK 18113340A HK 1254200 A1 HK1254200 A1 HK 1254200A1
Authority
HK
Hong Kong
Prior art keywords
hydroxy
carbon
hif
formula
olean
Prior art date
Application number
HK18113340.0A
Other languages
English (en)
Chinese (zh)
Inventor
爱德华多‧穆尼奥斯布兰科
愛德華多‧穆尼奧斯布蘭科
阿尔贝托‧米纳西
玛丽亚‧卢斯‧贝利多卡韦略德阿尔瓦
阿爾貝托‧米納西
乔瓦尼‧阿彭迪诺
瑪麗亞‧盧斯‧貝利多卡韋略德阿爾瓦
喬瓦尼‧阿彭迪諾
Original Assignee
维瓦赛尔生物技术西班牙有限公司
維瓦賽爾生物技術西班牙有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 维瓦赛尔生物技术西班牙有限公司, 維瓦賽爾生物技術西班牙有限公司 filed Critical 维瓦赛尔生物技术西班牙有限公司
Publication of HK1254200A1 publication Critical patent/HK1254200A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/08—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18113340.0A 2016-10-13 2017-10-03 氧肟酸三萜系化合物衍生物 HK1254200A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16193684.4 2016-10-13
EP16193684 2016-10-13
PCT/EP2017/075042 WO2018069086A1 (en) 2016-10-13 2017-10-03 Hydroxamate triterpenoid derivatives

Publications (1)

Publication Number Publication Date
HK1254200A1 true HK1254200A1 (zh) 2019-07-12

Family

ID=57136723

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18113340.0A HK1254200A1 (zh) 2016-10-13 2017-10-03 氧肟酸三萜系化合物衍生物

Country Status (14)

Country Link
US (1) US10766855B2 (https=)
EP (1) EP3365351B1 (https=)
JP (1) JP6598224B2 (https=)
KR (1) KR102038930B1 (https=)
CN (1) CN108368150B (https=)
AU (1) AU2017341257B2 (https=)
BR (1) BR112018068996A2 (https=)
CA (1) CA3020387C (https=)
ES (1) ES2774198T3 (https=)
HK (1) HK1254200A1 (https=)
IL (1) IL259391B (https=)
MX (2) MX364919B (https=)
RU (1) RU2018136782A (https=)
WO (1) WO2018069086A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020157494A1 (en) * 2019-01-30 2020-08-06 Rothamsted Research Ltd Cylodimer of dehydrosalicortin and derivatives thereof isolated from plant of the genus salix for use in cancer therapy
CN114805469A (zh) * 2021-01-27 2022-07-29 中国科学院上海药物研究所 含吡唑的白桦脂酸类衍生物，其制备方法及用途
CN117567544A (zh) * 2021-04-27 2024-02-20 中国医学科学院药物研究所 一类具有α,β-不饱和酮结构五环三萜类化合物在预防和治疗神经退行性疾病中的用途
WO2024145502A1 (en) * 2022-12-29 2024-07-04 The Board Of Regents Of The University Of Texas System Synthetic triterpenoids and compositions thereof in weight management, skeletal muscle function, and appetite suppression
CN119504913B (zh) * 2024-11-18 2025-09-26 南京中医药大学 一类五环三萜衍生物及其医药用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002322068A (ja) * 2001-02-26 2002-11-08 Japan Science & Technology Corp 血管再生促進剤
KR100821649B1 (ko) * 2006-01-24 2008-04-11 서울시립대학교 산학협력단 클리오퀴놀을 유효성분으로 포함하는 ＨＩＦ-1α 활성제
CN101367861A (zh) * 2007-08-15 2009-02-18 中国药科大学 2-羟基-3-脱氧五环三萜类化合物及其衍生物、其制备方法及用途
PL2252283T3 (pl) * 2008-01-11 2019-09-30 Reata Pharmaceuticals, Inc. Syntetyczne triterpenoidy i sposoby zastosowania w leczeniu choroby
WO2009146216A2 (en) * 2008-04-18 2009-12-03 Reata Pharmaceuticals. Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
US20100144688A1 (en) * 2008-12-10 2010-06-10 Advanced Life Sciences, Inc. 23-Substituted Derivatives of Lupane-type Pentacyclic Triterpenoids
KR101811462B1 (ko) * 2010-01-11 2018-01-25 피닉스 바이오테크놀러지 인코포레이티드. 협죽도 추출물을 포함하는 신경질환 치료용 조성물
CN102180939B (zh) 2011-03-30 2013-02-20 沈阳化工大学 一种抗肿瘤活性的熊果酸化学修饰物及其制备方法
US8324264B1 (en) * 2011-07-22 2012-12-04 Sequoia Sciences, Inc. Inhibitors of bacterial biofilms and related methods
CN102499925B (zh) * 2011-10-21 2015-11-11 上海中医药大学 一种中性粒细胞弹性蛋白酶抑制剂

Also Published As

Publication number Publication date
KR102038930B1 (ko) 2019-11-05
AU2017341257A1 (en) 2018-11-01
AU2017341257B2 (en) 2019-08-08
IL259391A (en) 2018-07-31
MX2019005448A (es) 2019-07-04
CN108368150A (zh) 2018-08-03
RU2018136782A (ru) 2020-04-20
US10766855B2 (en) 2020-09-08
WO2018069086A1 (en) 2018-04-19
MX2018006429A (es) 2018-09-27
CA3020387C (en) 2020-07-28
IL259391B (en) 2019-10-31
RU2018136782A3 (https=) 2020-04-20
BR112018068996A2 (pt) 2019-01-22
KR20180117700A (ko) 2018-10-29
ES2774198T3 (es) 2020-07-17
EP3365351B1 (en) 2019-12-04
EP3365351A1 (en) 2018-08-29
CN108368150B (zh) 2022-02-25
US20190367447A1 (en) 2019-12-05
CA3020387A1 (en) 2018-04-19
JP6598224B2 (ja) 2019-10-30
MX364919B (es) 2019-05-13
JP2019519464A (ja) 2019-07-11

Similar Documents

Publication Publication Date Title
CN108368150B (zh) 氧肟酸三萜系化合物衍生物
JP6129084B2 (ja) Ｃ４−モノメチルトリテルペノイド誘導体およびその使用方法
KR102101774B1 (ko) 바독솔론 메틸의 2,2-다이플루오로프로피온아미드 유도체, 그의 다형태 및 사용 방법
US9457033B2 (en) Steroid alkaloids and uses thereof as antimicrobial agents against electron transport-deficient microbes and as potentiators for antimicrobial agents against pathogenic bacteria
KR102237359B1 (ko) 올레아놀산의 ｃ１７―알칸디일 및 알켄디일 유도체 및 그의 사용 방법
Moodley et al. Phosphodiesterase 4 inhibitors augment the ability of formoterol to enhance glucocorticoid-dependent gene transcription in human airway epithelial cells: a novel mechanism for the clinical efficacy of roflumilast in severe chronic obstructive pulmonary disease
US9896475B2 (en) Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole
JPWO1999004815A1 (ja) コレステロール低下作用を有する医薬組成物
EP2868662A1 (en) Stable pantetheine derivatives for the treatment of pantothenate kinase associated neurodegeneration (pkan) and methods for the synthesis of such compounds
US20130225540A1 (en) Suppression of glial fibrillary acidic protein
KR20180107261A (ko) Myc 조정제로서의 MAX 결합제 및 그의 용도
JP2011528354A (ja) 抗生物質
Varghese et al. Polyaminohydroxamic acids and polyaminobenzamides as isoform selective histone deacetylase inhibitors
JP6619349B2 (ja) 新規なカンナビゲロール誘導体
US20210317070A1 (en) Cannabidiol derivatives as inhibitors of the hif prolyl hydroxylases activity
CN112898371A (zh) 一类人参三醇类化合物及其制备方法和医用用途
Saito et al. Synthesis and biological evaluation of biotin conjugates of (±)-(4bS, 8aR, 10aS)-10a-ethynyl-4b, 8, 8-trimethyl-3, 7-dioxo-3, 4b, 7, 8, 8a, 9, 10, 10a-octahydro-phenanthrene-2, 6-dicarbonitrile, an activator of the Keap1/Nrf2/ARE pathway, for the isolation of its protein targets
WO2017209270A1 (ja) ２５－ヒドロキシコレステロール又はその類縁体コレステロールを有効成分として含有してなる、活性化されたｔ細胞及び／又はｂ細胞に選択的な細胞死誘導剤又は細胞死促進剤
Yang et al. Design, Semi-Synthesis, and Antibacterial Activities of Triterpenoid-Hydrazone Conjugates
US11077116B2 (en) Isoxazole derivatives as inducers of fetal hemoglobin in erythroid precursor cells from beta-thalassemic patients
WO2026055707A1 (en) Short chain fatty acid analogues for targeted mucosal function
HK1229783B (zh) 新大麻萜酚衍生物
HK1207299B (zh) 用於抑制肌萎缩的方法